Ryan J. Brisson
YOU?
Author Swipe
View article: Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemic
Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemic Open
Purpose: Patients with cancer are particularly vulnerable to coronavirus disease (COVID). Transportation barriers made travel to obtain medical care more difficult during the pandemic. Whether these factors led to changes in the distance t…
View article: Data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Purpose: Squamous cell carcinoma of the head and neck (SCCHN) is a lethal cancer with a suboptimal 5-year overall survival of approximately 50% with surgery and/or definitive chemoradiotherapy. Novel treatments are thus urgently awaited. I…
View article: Supplementary data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Supplementary data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Supplementary Figure 1. TCR-β DI in HPV-positive patients (excluding smokers with {greater than or equal to}10packyear history) versus HPV-negative patients (excluding patients with
View article: Data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Purpose: Squamous cell carcinoma of the head and neck (SCCHN) is a lethal cancer with a suboptimal 5-year overall survival of approximately 50% with surgery and/or definitive chemoradiotherapy. Novel treatments are thus urgently awaited. I…
View article: Supplementary data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Supplementary data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Supplementary Figure 1. TCR-β DI in HPV-positive patients (excluding smokers with {greater than or equal to}10packyear history) versus HPV-negative patients (excluding patients with
View article: Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors
Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors Open
Background The authors hypothesized that patients developing immune‐related adverse events (irAEs) while receiving immune checkpoint inhibition (ICI) for recurrent/metastatic head and neck cancer (HNC) would have improved oncologic outcome…
View article: The role of chemotherapy in the management of olfactory neuroblastoma: A 40‐year surveillance, epidemiology, and end results registry study
The role of chemotherapy in the management of olfactory neuroblastoma: A 40‐year surveillance, epidemiology, and end results registry study Open
Background In this retrospective surveillance, epidemiology, and end results (SEER) registry analysis, we investigated the role of chemotherapy (CT) in the treatment of olfactory neuroblastoma (ON), an exceedingly rare sino‐nasal tumor typ…
View article: A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study Open
Background Patients with cetuximab‐resistant, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) have poor outcomes. This study hypothesized that dual blockade of mammalian target of rapamycin and epidermal growth factor re…
View article: A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma Open
Background MET signaling is a well described mechanism of resistance to anti‐EGFR therapy, and MET overexpression is common in head and neck squamous cell carcinomas (HNSCCs). In the current trial, the authors compared the oral MET inhibit…
View article: A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer
A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer Open
Background This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Methods Twelve patients wit…
View article: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer Open
Ann Oncol 2019; (doi:10.1093/annonc/mdy522) In the original article, the wrong supplementary material was accidentally uploaded. This has now been corrected. The Publisher apologizes for the error. OPTIMA: a phase II dose and volume de-esc…
View article: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer Open
Clinical trials.gov identifier: NCT02258659.
View article: Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer Open
A retrospective review of NSCLC patients treated with anti-PD-1/PD-L1 monotherapy. Patients with innate resistance to anti-PD-1/PD-L1 therapy (defined as progression at first CT evaluation) were compared to patients with initial clinical b…
View article: Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Purpose: Squamous cell carcinoma of the head and neck (SCCHN) is a lethal cancer with a suboptimal 5-year overall survival of approximately 50% with surgery and/or definitive chemoradiotherapy. Novel treatments are thus urgently awaited. I…